Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 61,350 $ 97,428
Short-term investments 45,603 102,791
Accounts receivable 9,966 6,170
Note receivable from Viking Therapeutics 3,207 4,782
Inventory 3,835 1,633
Other current assets 2,602 1,908
Total current assets 126,563 214,712
Deferred income taxes 133,595 189,083
Investment in Viking Therapeutics 18,733 29,728
Intangible assets, net 210,142 48,347
Goodwill 72,360 12,238
Commercial license rights, net 26,141 8,554
Property and equipment, net 1,181 372
Other assets 603 27
Total assets 589,318 503,061
Current liabilities:    
Accounts payable 2,336 4,083
Accrued liabilities 4,951 5,397
Current contingent liabilities 5,337 10,414
Current lease exit obligations 239 934
2019 convertible senior notes, net 207,363 201,985
Other current liabilities 121 8
Total current liabilities 220,347 222,821
2019 convertible senior notes, net 0 0
Long-term contingent liabilities 4,138 3,033
Other long-term liabilities 398 297
Total liabilities 224,883 226,151
Commitments and Contingencies
Stockholders' equity:    
Common stock, $0.001 par value; 33,333,333 shares authorized; 20,853,127 and 19,949,012 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively 21 20
Additional paid-in capital 755,049 661,850
Accumulated other comprehensive income 3,745 4,903
Accumulated deficit (429,053) (429,491)
Total stockholders' equity attributable to Ligand Pharmaceuticals 329,762 237,282
Total liabilities and stockholders' equity $ 589,318 $ 503,061